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ABSTRACT
The cost-effectiveness of adding the two health insurance covered thiazolidinediones (TZDs)- rosiglitazone or pioglitazone, to
metformin in treating type 2 diabetes mellitus was assessed from a Taiwanese National Health Insurance (NHI) perspective.
This analysis was based on patient-level data extracted from Taiwan’s NHI databases. Type 2 diabetic patients who received consecutive metformin treatments between 2001 and 2005 were identified. Clinical effectiveness, a proxy of glycemic control (time to insulin
dependence), and direct medical cost were also estimated. Incremental cost-effectiveness ratio (ICER) was calculated and expressed as
cost per delayed year to insulin dependence.
Compared to add-on non-TZDs, add-on rosiglitazone and pioglitazone were associated with delays of additional 151 days (0.41 years)
and 101 days (0.28 years) in insulin dependence, respectively. Total mean medical costs were higher in add-on TZDs users compared to
add-on non-TZDs users. The additional total medical costs of add-on rosiglitazone or pioglitazone were comparable, with ICERs of 95,874
and 95,485 New Taiwan (NT) dollars per year delay in insulin dependence, respectively.
Add-on TZDs improves glycemic control but also increases direct medical cost. In terms of the incremental medical costs associated
with these clinical benefits, add-on rosiglitazone or pioglitazone are similar in Taiwan.
Key words: thiazolidinediones (TZDs), cost-effectiveness, incremental cost-effectiveness ratio (ICER), diabetes mellitus, national health
insurance

INTRODUCTION
The clinical and economic consequences of type 2
diabetes mellitus, with its increasing prevalence and increased
risk of macrovascular and microvascular complications, made
it a significant public health issue of concern. According to the
World Health Organization, the prevalence of diabetes across
all age-groups worldwide was estimated at 2.8% in 2000 and
predicted to be 4.4% in 2030(1). Prevalence of type 2 diabetes
mellitus in Taiwan is also high. The estimated national prevalence in 2001 was 3.13%. The prevalence among adults over
45 years old is of particular concern. According to the 2004
Report on Healthcare Quality in Diabetes Mellitus, the prevalence of type 2 diabetes mellitus among Taiwanese adults age
45-64 and age over 65 years old were 7.18% and 15.32%,
respectively, in 2001. It is noteworthy that the prevalence
gradually increased over a three-year period (prevalence
* Author for correspondence. Tel: +886-02-23123456 ext.88347;
E-mail: fyshsiao@ntu.edu.tw

in 2003, age 45-64 and over 65 years old were 7.71% and
15.32%, respectively)(2).
Diabetes mellitus inflicts considerable burden on both
the patient and the national healthcare budget(3). The cost of
diabetic-related complications, especially the macrovascular
(cardiovascular) complications, is the main cost driver(4). It
is well-established that aggressive management of hyperglycemia to maintain tight glycemic control can substantially reduce the risk of complications resulted from type 2
diabetes(5,6) and costs(7,8). However, due to potential harmful
effect of intensive insulin therapy on macrovascular events in
recent literatures(9,10), the selection of second-step diabetic
management for patients who fail to achieve their glycemic
control has become a dilemma.
Both rosiglitazone and pioglitazone are members of the
thiazolidinediones (TZDs) class of oral antidiabetic drugs
(OAD) that improve glycemic control by reducing the body’s
resistance to insulin(11). With this promising mechanism,
TZDs offered potential benefits in type 2 diabetic patients.
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Their use spread quickly throughout the United States,
Taiwan, and other countries for the treatment of type 2
diabetes mellitus since they entered the market. According to
data derived from the National Prescription Audit (NPA), the
use of TZDs in the US continued to increase and peaked at
34% of total visits with a diabetic treatment in 2005 since the
introduction of rosiglitazone and pioglitazone in 1999(12). In
Taiwan, the Bureau of National Health Insurance (NHI) also
reported that annual prescriptions of TZDs (rosiglitazone and
pioglitazone) increased from 1.42% to 10.78% of all prescriptions of antidiabetic agents for type 2 diabetes patients over a
three-year period (2001-2003)(2).
However, the high price and increased utilization of
TZDs among diabetic patients in Taiwan raises significant
concern from a financial perspective. To enable healthcare
payers to budget appropriately, estimating the cost of new
treatment becomes more important as increasing costs stretch
limited health care resources, especially in the Taiwanese
government-run mandatory health care system. International
experiences have demonstrated the value of economic evaluation for decision makers in the health care sector; however,
while there were several cost-effectiveness studies in TZDs
conducted in other countries(13-16), none has ever been
performed in Taiwan. In addition, most of the studies derived
their effectiveness data from clinical trials or meta-analyses
and implemented cost data from their own countries. These
results cannot be applied to other countries because of the
differences in health-care system and resource utilization
patterns. Therefore, the objective of our study was to conduct
a cost-effectiveness analysis to evaluate TZDs (rosiglitazone
or pioglitazone) as add-on therapy for treatments in type 2
diabetic patients in the NHI system in Taiwan.

MATERIALS AND METHODS
From a national health insurance system perspective, this
study estimated the cost-effectiveness of adding TZDs (rosiglitazone or pioglitazone) compared to older treatments among
type 2 diabetic patients already on metformin. TZDs are only
indicated in Taiwan as an add-on to type 2 diabetic patients
who cannot maintain their blood glucose level by conventional
OAD. Therefore, our study cohorts were stratified based on
whether patients received an add-on of TZDs (rosiglitazone,
pioglitazone) or other non-TZDs OAD (metformin, sulfonylureas (chlorpropamide, glibornuride, gliclazide, glimepiride,
gliquidone, glipizide, glyburide, tolazamide, tolbutamide,
nateglinide, repaglinide, and acarbose) following treatment
of metformin for at least 3 consecutive prescriptions. Patients
who remained on monotherapy or used insulin directly after
the metformin therapy were not included in our study cohort.
I. Data Source
The analysis was based on the 2000-2005 Taiwan’s
NHI databases. Launched in 1995, Taiwan’s NHI system is a
mandatory, single-payer, health insurance program organized

by the government and operated by the Bureau of NHI in
Taiwan. With approximately 23 million insured, it covers
over 99% of the population in Taiwan.
The Bureau of NHI, Taiwan and the National Health
Research Institutes (NHRI), Taiwan, maintains a database
of uniquely identified claims and transactions for all covered
services utilized by patients enrolled in the program. This
database includes information on demographic, clinical,
medical resource utilization (outpatient and inpatient visits),
costs of services, and treatment patterns. The completeness
and accuracy of the NHI claims databases are also ensured
by the Bureau of NHI and NHRI, Taiwan(17).
II. Study Cohort
Patients with type 2 diabetes were identified from
Taiwan’s NHI claims database. The inclusion criteria reflected
patients who had their first ambulatory visits with a diagnosis
of diabetes mellitus (ICD-9CM codes: 250.xx) and received at
least three consecutive prescriptions for metformin between
2001 and 2005. The cohort entry date (index date) for each
patient was defined as the date when the oral hypoglycemic
treatment was first prescribed. Patients were excluded if they
had type 1 diabetes (ICD-9CM codes: 250.x1) or if they took
insulin only during the study period.
III. Effectiveness
The clinical effectiveness measure is the time to the
commencement of insulin dependence with at least three
consecutive claims of insulin, which is presumed to reflect
the treatment failure with OAD. According to the International Diabetes Federation guidelines(11), when glycemic
target cannot be achieved with OAD alone, insulin therapy
could be initiated. Insulin dependence was defined as the date
of the first insulin claim when patients start receiving three
consecutive insulin prescriptions. Patients who did not have
events of insulin initiation were censored at the end of study
period (December 31, 2005). The mean follow-up time of our
study subjects were 926.68 days (2.35 years).
IV. Costs
The perspective taken for estimating costs was that of
the Taiwan’s NHI. All direct medical costs were based on
the reimbursement cost and treatment practice obtained from
the Taiwan’s NHI system. All costs were expressed in New
Taiwan (NT) dollars (currency exchange rate of June, 2011,
28 NT dollars = 1 US dollar).
Diabetic medication costs were the sum of study medication, i.e., rosiglitazone (4 mg, NHI reimbursement price:
NT 39 dollars) or pioglitazone (30 mg, NHI reimbursement
price: NT 59 dollars), and other hyperglycemic medications.
All costs were based on the number of doses and days taken
for each medication reimbursed by the NHI system in Taiwan.
In addition to diabetic medication cost, direct medical costs
including any cost incurred for either outpatient or inpatient
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services in the NHI system were calculated. Direct medical
costs for claims with diabetes-specific codes were separated
from other outpatient costs to estimate the cost of managing
type 2 diabetes mellitus in routine clinical practice. Other
outpatient costs irrelevant to type 2 diabetes mellitus were
summed as a separate category, outpatient visit cost (others).
V. Statistical Analyses
Regression models were used to evaluate the association between the time to insulin dependence and the selection
of TZDs versus other OADs as add-on therapy. All analyses
controlled patient demographics (age and gender), severity of
diabetes (diabetic hospitalizations), comorbidities (Charlson
comorbidity index and CV diseases), other medical conditions (hypertension, hyperlipidemia and chronic kidney
diseases) and physician specialty (endocrinologist). Data for
severity of diabetes and comorbidities were based on participants’ inpatient claims data during the 12 months prior to the
index date. Other medical conditions were obtained from the
outpatient claims 12 months prior to the index date.
Cost-effectiveness was expressed in terms of the incremental cost-effectiveness ratio (ICER) for the add-on TZDs
arms versus add-on of non-TZDs OADs. The ICER was
calculated as the additional resource consumption needed
for an increase in an additional unit of effectiveness. More
specifically, the ICER reports the additional cost per additional day delayed in insulin dependence for patients treated
with add-on rosiglitazone or pioglitazone compared to those
with add-on conventional OADs (non-TZDs).

RESULTS
I. Patient Population
Among 61,925 newly diagnosed type 2 diabetic patients
with three consecutive metformin prescriptions, there were

Figure 1. Flowchart of the study cohort.

24,928 patients who took combination therapy during the
follow-up. Patients whose add-on drugs included both
rosiglitazone and pioglitazone were excluded to avoid
cross-over effect. We therefore identified 24,654 patients
with type 2 diabetes mellitus who met our inclusion/exclusion criteria between 2001 and 2005. Our study cohort was
further stratified based on their add-on drugs, which included
2,699 (10.95%) patients who received add-on rosiglitazone,
714 (2.90%) pioglitazone and 21,241 (86.17%) conventional
(non-TZDs) OAD during the follow-up period (Figure 1).
The age and gender distribution, medical history and
comorbidities between TZDs and non-TZDs users were similar
(Table 1). A slightly higher proportion of those prescribed
TZDs (1.82%) had a previous history of angina pectoris than
those prescribed an add-on of non-TZDs (1.08%). Patients
who were prescribed an add-on rosiglitazone (27.49%)
or pioglitazone (26.61%) also were more likely to have a
previous history of hyperlipidemia than those were prescribed
an add-on of non-TZDs (24.80%). A much higher proportion
of pioglitazone patients saw an endocrinologist.
II. Effectiveness
Based on our regression models, the use of TZDs as
add-on therapy compared to non-TZD add-on therapy was
associated with a delay of insulin dependence. Rosiglitazone
and pioglitazone were associated with an additional 151 days
(p < 0.001) and 101 days (p < 0.001) of delay, respectively, in
insulin dependence. Patients who saw an endocrinologist for
their diabetes mellitus management had a prolonged time to
insulin dependence while those with a Charlson comorbidity
index greater than 2 had a shorter time to insulin dependence.
Severity of diabetes was non-significantly associated with a
shorter time to insulin dependence (Table 2).
III. Costs and Incremental Cost-Effectiveness
Compared to patients who added non-TZDs, those who
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Table 1. Baseline characteristics at cohort entry

Metformin
(n = 24,654)
+ Rosiglitazone

+ Pioglitazone

(n = 2,699)

+ Non-TZDs

(n = 714)

P-value

(n = 21,241)

n

%

n

%

n

%

Age, mean(SD), y

56.16

13.37

54.77

Male

1,400

51.87

350

12.90

57.42

13.31

49.02

10,702

50.38

0.250

109

4.04

16

2.24

861

4.05

0.052

Composite CV events

103

Myocardial infarction

8

3.82

26

3.64

777

3.66

0.918

0.30

5

0.70

106

0.50

0.250

Congestive heart failure
Stroke

6

0.22

1

0.14

78

0.37

0.307

39

1.44

9

1.26

350

1.65

0.549

Angina pectoris

49

1.82

13

1.82

230

1.08

0.001

Transient ischemic attack

9

0.33

0

0.00

79

0.00

0.255

PTCA

18

0.67

5

0.70

108

0.51

0.464

CABG

6

0.22

2

0.28

20

0.09

0.072

22

0.82

1

0.14

210

0.99

0.053

Characteristics

Prior diabetic hospital admissions
History of CV disease

Charlson comorbidity index
2+
History of other medical conditions
Hypertension

1,138

42.16

282

39.50

8,623

40.60

0.234

Hyperlipidemia

742

27.49

190

26.61

5,267

24.80

0.007

Chronic kidney diseases

20

0.74

6

0.84

116

0.55

0.289

680

25.19

286

40.06

5,464

25.72

<0.001

Physician specialty
Endocrinologist

Abbreviations: CV = cardiovascular; PTCA = percutaneous transluminal coronary angioplasty; CABG = coronary artery bypass graft surgery ;

Table 2. Model adjusted time to permanent insulin initiation (days)
Parameter

Parameter Estimate

Standard Error

P-value

+ Rosiglitazone

151.03

9.91

<0.001

+ Pioglitazone

101.07

18.49

<0.001

Add on treatment dummy*
(ref: + Non-TZDs)

Covariates**
age (yr)

0.58

0.24

0.02

-29.29

6.21

<0.001

Prior diabetic hospital admissions

-21.19

19.82

0.29

Charlson comorbidity index (>= 2)

-125.71

11.21

<0.001

gender (male)

Endocrinologist
Constant form

41.57

7.13

<0.001

892.42

14.87

<0.001

*Compared to add-on non-TZDs, add-on rosiglitazone was associated with an additional 151 days (p < 0.001) and pioglitazone was associated
with an additional 101days (p < 0.001) of delay in insulin dependence.
**Male patients were associated with a shorter time to insulin initiation (29 days shorter than female patients). Patients with a Charlson comorbidity index greater than 2 had a shorter time to insulin initiation (125 days shorter than those with less comorbidities) while those who saw
an endocrinologist for their diabetes mellitus management had a prolonged time to insulin dependence (41 days longer than those who did
not).
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Table 3. Direct medical costs during patient follow-up

Metformin
+ Rosiglitazone
Cost (per patient); NT dollars
Total direct costs
Treatment costs (diabetic medications)
Outpatient visit cost

+ Pioglitazone

+ Non-TZDs

mean

SD

mean

SD

mean

SD

153,162

199,181

139,931

188,852

113,492

177,030

16,895

16,967

18,697

18,419

6,183

6,692

89,114

103,407

85,518

123,926

65,984

81,674

Diabetes mellitus-related

24,150

38,427

23,411

28,426

16,322

22,039

Others

64,964

95,503

62,107

119,066

49,663

76,954

47,153

142,649

35,716

102,942

41,325

136,181

Hospitalization cost

*NT dollars: New Taiwan dollars, Currency exchange rate (June, 2011), 28 NT dollars = 1 US dollars.

Table 4. Incremental cost-effectiveness (add-on rosiglitazone or pioglitazone vs non-TZDs)
Adjusted
effectiveness
(days)
(years)

Total medical cost

difference

ICER

(NT dollars)

Add-on treatment
+ Non-TZD

113,492

+ Rosiglitazone

151.03

0.41

153,162

39,670

95,874

+ Pioglitazone

101.07

0.28

139,931

26,439

95,485

Adjusted effectiveness: delay in starting insulin treatment.
ICER: incremental cost-effectiveness ratio.
NT dollars: New Taiwan dollars, Currency exchange rate (June, 2011), 28 NT dollars = 1 US dollars.

added TZDs had higher total medical cost (NT dollars, mean;
add-on rosiglitazone: 153,162, add-on pioglitazone: 139,931,
add-on non-TZDs: 113,492) during the follow-up period. A
breakdown of total medical cost per patient demonstrated
that the major cost differences were associated with diabetic
medication and outpatient visit costs. Diabetic medication
costs were approximately three times as great among patients
on add-on TZDs versus non-TZDs (NT dollars, mean; add-on
rosiglitazone: 16,895, add-on pioglitazone: 18,697, add-on
non-TZDs: 6,183) during the follow-up. Among all groups,
patients who were prescribed an add-on of rosiglitazone
were associated with the highest outpatient visit cost (89,114
[103,407] NT dollars) and hospitalization cost (47,153 NT
dollars) (Table 3).
Using the adjusted results from the regression model and
converting the estimated time to start insulin treatment from
days to years, rosiglitazone and pioglitazone delayed time
to insulin dependence by 0.41 and 0.28 year, respectively,
compared to non-TZDs. Combining the cost and effectiveness results, the additional total medical costs of add-on rosiglitazone or pioglitazone were comparable, with the ICERs
of 95,874 and 95,485 NT dollars per year delay to start insulin
treatment, respectively (Table 4).

DISCUSSION
Combination use of OADs has been highly recommended

for patients with suboptimal glycemic control to delay the
disease progression and to reduce the long-term risks of
macrovascular and microvascular complications(18). The
current study in type 2 diabetic patients showed that the
add-on of TZDs, compared to that of non-TZDs, was associated with a delay in insulin dependence. At the same time,
adding TZDs resulted in higher medical costs. Our empirical
findings on glycemic effect are in line with previous findings with combination use of rosiglitazone(19) or pioglitazone
plus metformin(20). Furthermore, our study presented additional clinical benefits by comparing the add-on of TZDs and
non-TZDs, which would provide more evidence in selecting
the add-on agents when the monotherapy fail to maintain
glycemic control over time.
Insulin is one of the second steps among the stepwise
strategies to manage type 2 diabetes. Other steps after
patients who failed their life style modification and metformin
included add-on another oral hypoglycemic agents (such as
sulfonylurea or TZD)(21). Most type 2 diabetic patients will
ultimately become insulin-dependent because of disease
progression or the failure of OADs use to maintain glycemic
control. Although insulin might be the most effective agent in
maintaining blood glucose, only few insulin-treated patients
achieve glycemic goals due to poor compliance(22,23). Findings from the UK Prospective Diabetes Study (UKPDS) have
indicated that 27% of patients prescribed insulin refused
treatment(22). Results from another study have suggested
that adherence to insulin therapy among patients with type
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2 diabetes was approximately 60%(23). Numerous factors are
likely to contribute to patient reluctance, the main driving
force behind poor compliance to insulin treatment. Studies
have shown that patients may equate insulin initiation with
worsening diabetes, with their own personal failure to
manage their disease, or with concern about needles or injections in public, the potential complexity of insulin regimens,
hypoglycemia, or weight gain(24,25).
The launch of rosiglitazone and pioglitazone expanded
the treatment options of OADs combination therapy in type
2 diabetic patients. Based on the results of a large, systematic meta-analysis, the two thiazolidinediones appear to have
similar effects on glycemic control and similar side-effect
profiles(26). However, from the policy-maker’s perspective, it
is important to distinguish these two agents in terms of medical
resource utilization. Previous studies from the perspective of
the UK payer system(27) and US payer system(28) have indicated that pioglitazone plus metformin represented a dominant
treatment strategy compared to rosiglitazone plus metformin
over the lifetime of simulated type 2 diabetic patients and the
moderately lower medical costs were largely due to reduced
cardiovascular complications. Our study found that the additional total medical costs of add-on rosiglitazone (NT 95,874)
or pioglitazone (NT 95,485) were similar. However, in light
of a public meeting held in July 2010 by the US Food and
Drug Administration (FDA) to discuss risks and benefits of
rosiglitazone, it is noteworthy that add-on pioglitazone was
slightly dominant in terms of cost-effectiveness in our study.
This study has several potential limitations. First, our
clinical effectiveness measure is based on the time to insulin
dependence, rather than life years gained or quality-adjusted
life years (QALYs) gained. However, we believed that the
delay of time to insulin dependence is still a good surrogate
for QALYs in type 2 diabetic patients because glycemic
control is a top priority for this patient population and patients
prefer to avoid using insulin because of many reasons. We
acknowledged that patients’ attitude may play an important
role in insulin initiation. However, we were unable to capture
this because of our retrospective observational study design.
In addition, our multivariable linear regression may not fit
the outcome very well since we can only obtain our predictor
variables (such as patients’ comorbidities) from the claimbased database. A second limitation is that we did not calculate macrovascular event rates in our study; however, we did
include medical cost for management diabetic complications,
including macrovascular events in our cost analysis.

CONCLUSIONS
Based on our study, TZDs as add-on to existing diabetic
treatment was associated with delayed time to insulin dependence. In terms of the incremental medical costs associated
with these clinical benefits, add-on rosiglitazone and pioglitazone are similar in the NHI system in Taiwan, with a slightly
more favorable profile for pioglitazone.
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